Cite

HARVARD Citation

    Cohen, M. et al. (2021). BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Multiple sclerosis. pp. 1556-1563. [Online]. 
  
Back to record